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Logic models to predict continuous 
outputs based on binary inputs 
with an application to personalized 
cancer therapy
Theo A. Knijnenburg1, Gunnar W. Klau2, Francesco Iorio3, Mathew J. Garnett4, 
Ultan McDermott4, Ilya Shmulevich1 & Lodewyk F. A. Wessels5
Mining large datasets using machine learning approaches often leads to models that are hard to 
interpret and not amenable to the generation of hypotheses that can be experimentally tested. 
We present ‘Logic Optimization for Binary Input to Continuous Output’ (LOBICO), a computational 
approach that infers small and easily interpretable logic models of binary input features that explain 
a continuous output variable. Applying LOBICO to a large cancer cell line panel, we find that logic 
combinations of multiple mutations are more predictive of drug response than single gene predictors. 
Importantly, we show that the use of the continuous information leads to robust and more accurate 
logic models. LOBICO implements the ability to uncover logic models around predefined operating 
points in terms of sensitivity and specificity. As such, it represents an important step towards practical 
application of interpretable logic models.
Regression and classification models are important tools for researchers in various fields. The application of 
these many-to-one mapping models is two-fold. First, they can be used for prediction. The output value or class 
of a (new) case can be predicted by applying the inferred mapping to the input variables of the case. Second, 
they inform us about the relationship between the input and the output. They specify how the input variables 
are (mathematically) interacting with each other to produce the output variable. The usefulness of the second 
application is, however, limited by the power of the human intellect. We suggest that the interpretation of these 
many-to-one mapping models is of utmost, yet undervalued, importance in many research fields.
This also holds for computational biology, where a multitude of molecular and genomic data is frequently used 
to explain or predict a biological or clinical phenotype. Single predictor models are generally not accurate enough, 
reflecting the importance of acknowledging the interaction between biological components. On the other hand, 
machine learning approaches, such as Elastic Net1 and Random Forests2 produce complex multi-predictor mod-
els that are hard to interpret and not amenable to the generation of hypotheses that can be experimentally tested. 
As a consequence, such models are not likely to further our understanding of biology. There is an urgent need 
for approaches that build small, interpretable, yet accurate models that capture the interplay between biological 
components and explain the phenotype of interest.
In this study, we have developed such a modeling framework to explain drug response of cancer cell lines 
using gene mutation data. Our approach, ‘Logic Optimization for Binary Input to Continuous Output’ (LOBICO) 
infers small and easily interpretable logic models of gene mutations (binary input variables) that explain the 
observed sensitivity to anticancer drugs in the cell lines (continuous output).
The contributions of our approach are three-fold: First, the continuous information of the output variable is 
retained in the logic mapping. The output variable is binarized, which facilitates its interpretation, yet the dis-
tances of the continuous values to the binarization threshold are used in the inference. Second, LOBICO provides 
the user with the option to include constraints on the model performance that allows the identification of logic 
models around operating points predefined in terms of sensitivity and specificity. This enables tailoring of the 
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model to, for example, clinical applications where the severity of diseases or side effects of the treatment dictate a 
desired level of specificity or sensitivity. Third, the logic mapping is formulated as an integer linear programming 
problem (ILP). This means that advanced ILP solvers can be used to find an optimal logic mapping fast enough to 
apply LOBICO to large and complex datasets without the need to tune parameters.
Our work is similar in spirit to logic regression (LR)3,4, sparse combinatorial inference (SCI)5, Markov logic 
networks6,7, combinatorial association logic (CAL)8, CellNetOptimizer9 and genetic programming for association 
studies (GPAS)10, which all employ combinatorial logic to explicitly incorporate interactions in their models. The 
most important aspect in which LOBICO differentiates itself from these approaches is by its direct emphasis on 
interpretability. This is in contrast with the linearly weighted sums of logic functions as inferred by LR or the pos-
terior probabilities of predictors in the model averaged across an ensemble of many solutions as inferred by SCI. 
Graphical models, such as Bayesian networks11 and Markov random fields12 also facilitate interpretation, although 
due to their probabilistic nature they do not lend themselves to standard formal reasoning as well as logic models 
do. MOCA (Multivariate Organization of Combinatorial Alterations)13 deserves special attention as it has also 
been applied to predict drug response by inferring logic combinations of genomic input features. The most impor-
tant differences with our work are: (1) MOCA employs a heuristic, sub-optimal progressive selection of features 
to infer logic formulas, and (2) MOCA uses discretized drug response values and discards the information in the 
continuous values that LOBICO uses in its model inference. Moreover, LOBICO includes constraints on statistical 
performance criteria, such as a minimum specificity, which is a novel feature not available in any other approach.
Here, we demonstrate LOBICO by application to a large cancer cell line panel, where the goal is to explain drug 
response based on binary mutation data of a set of genes14. We investigate whether logic models perform better 
than single-gene predictors, and put genes that co-occur in logic models in the context of known cancer path-
ways. We assess whether using continuous output values provides benefit in terms of robustness and performance 
above the use of binarized data, which is usually the starting point for logical analysis of data15. We also provide 
a comparison with Elastic Net, Random Forests and LR. Finally, we explore the power and flexibility of the ILP 
formulation by inferring logic models around different operating points in the receiver-operator-characteristic 
(ROC) space. We show that the ability to find robust and interpretable models with a predefined balance between 
false positives and false negatives is an important step towards practical application of these models.
Results
Sensitivity to anticancer drugs as a logic combination of gene mutations. We used LOBICO to 
find the logic combinations of mutations that best explain the response of cancer cell lines to anticancer drugs. 
This analysis was based on a panel of 714 cancer cell lines from more than 50 tumor types for which the binary 
mutation status of 54 known cancer genes was obtained14. A gene was called mutated when it had a point muta-
tion, a small insertion or deletion as determined by capillary sequencing, or when it was highly amplified or 
homozygously deleted based on copy number arrays. Additionally, we included the presence or absence of 6 
known oncogenic gene fusions across these cell lines, resulting in a binary data matrix with a total of 60 features. 
The cell lines in the panel were screened against 142 anticancer drugs. The half-maximal inhibitory concentra-
tions at 72 hours (IC50s) obtained in this screen were used to represent the drug response and served as the con-
tinuous output variables. LOBICO was applied to the IC50s of each drug separately.
Figure 1 provides a schematic overview of the application of LOBICO to this dataset using the IC50s of the 
EGFR/ERBB2 inhibitor Afatinib as the output variable. For Afatinib, IC50s were obtained for 642 of the 714 cell 
lines. Although LOBICO uses the continuous values, it is also necessary to define a binarization threshold for 
the output variable. This threshold is used to divide the cell lines into two classes; the sensitive cell lines and the 
resistant cell lines. LOBICO finds an optimal logic function of binary mutation features that minimizes the error, 
which is defined as the sum of the weighted misclassified cell lines. A misclassification occurs when a sensitive 
cell line is predicted by the model to be resistant or vice versa. The weight is proportional to the distance to the 
binarization threshold. Consequently, misclassification of cell lines close to the binarization threshold does not 
considerably affect the optimization criterion, whereas there is a large penalty for misclassifying cell lines that are 
extremely sensitive or resistant to the drug. By default, the total weight associated with samples of each class is 
normalized in order to balance class importance. This is especially important for unbalanced classes as is often 
the case for the cell line panel, where we observed that, for most drugs, the bulk of cell lines are not affected, and 
only a small percentage (5–15% typically) end up in the class of sensitive cell lines. The optimization procedure 
is formulated as an integer linear programming (ILP) problem, which provides a practically efficient way to find 
optimal solutions. See Methods Section for more details.
Drug response is explained by multiple mutations. LOBICO finds logic models that are described in 
the disjunctive normal form (DNF), a standard notation in which every logic function can be expressed. The DNF 
is parameterized by two parameters: K, the number of disjuncts, and M, the number of terms per disjunct. We 
applied LOBICO with eight different parameter settings, i.e. from simple single predictor models (K = 1, M = 1) 
to more complex multi-predictor models (K > 1, M > 1). See Table 1 for examples of the eight models. A stratified 
10-fold cross-validation (CV) strategy was employed to select the appropriate model complexity, i.e. the one with 
the lowest CV error.
Application across all 142 drugs revealed that the large majority of drugs (85%) are best explained by 
multi-predictor models (Table 1, Supplementary Data 1 and 2). This number remains high (81%) if we only 
consider the 72 drugs for which the CV error is statistically significant at a FDR < 1% and p < 0.01. In many 
cases the multi-predictor model selected by CV was substantially better than the single predictor model (Fig. 2, 
Supplementary Figure 1). For example, LOBICO inferred a 4-input OR model for the MEK1/2 inhibitor PD− 
0325901, which had a CV error of 0.21 while the best single input model only reached 0.34. The 4-input OR 
model included the genes BRAF, NRAS, KRAS and HRAS. Thus, cell lines with a BRAF mutation or a mutation 
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in NRAS, KRAS or HRAS (members of the RAS protein family) are predicted to be sensitive to this drug. Since 
BRAF and RAS are directly upstream of MEK in the MEK-ERK pathway, this association is easily understood 
from pathway biology. In general, OR models will increase the number of cell lines (or patient population) that 
are predicted to respond to a drug. On the other hand, AND models refine the predictions. For example, LOBICO 
inferred that cell lines with a mutation in both tumor suppressors TP53 and CDKN2A specifically respond to 
the microtubule inhibitor Paclitaxel (Taxol). These results strengthen the notion that gene mutations should not 
be considered in isolation, but in relationship to one another, if they are to be used as prognostic biomarkers or 
predictors of therapy response.
We validated these models using an independent drug sensitivity dataset from the Cancer Therapeutics 
Response Portal (CTRP, 2nd version)16. Our analyses were restricted to those compounds (n = 47) overlapping 
with our own study. We explored two scenarios. In Scenario 1 we trained LOBICO models on our data using 
the 344 cell lines overlapping with CTRP and validated on the CTRP drug response measurements of these 344 
cell lines. In Scenario 2 we trained LOBICO models on the 377 cell lines that are unique to our dataset and then 
validated on the independent set of 344 CTRP cell lines. See Supplementary Figure 2 for an overview of these 
datasets. The results of these validation analyses are presented in Table 2. When training (using our data) and 
testing (using CTRP drug response) on the same cell lines (Scenario 1), we validated 5 of the 18 models (28%) that 
were statistically significant in the training phase, including both single and multi-input models (Supplementary 
Figures 3 and 4). Importantly, 4 of the 5 best performing models on our cell line panel were validated on CTRP 
with considerable statistical significance. Using the independent set of cell lines as a validation cohort (Scenario 
2) we found that the two best performing models on GDSC validated with high statistical significance in CTRP 
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Figure 1. Workflow of LOBICO. LOBICO has two main inputs: (1) a binary matrix of samples by features 
(depicted in the blue box). Here, the binary matrix contains the mutation status of 60 cancer genes measured 
across 642 cancer cell lines. (2) a continuous vector with a value for each of the samples (depicted in the orange 
boxes). In this case, the vector contains the IC50 of each cell line in response to Afatinib, an EGFR/ERBB2 
inhibitor. The continuous vector is transformed into a binary vector and a sample-specific weight vector using 
a binarization scheme. Particularly, the IC50s are binarized using a threshold leading to a set of sensitive and 
a set of resistant cell lines. The distances of the original IC50s to the binarization threshold are represented in 
the weight vector, which is normalized per class. Then, LOBICO finds the optimal logic model of features (gene 
mutations) that minimizes the total weight of misclassified samples (cell lines). In this case, the optimal 2-input 
OR logic formula is ‘EGFR OR ERBB2’ (depicted in the white box).
Model complexity Number of drugs best explained by 
indicated model complexity (%)
Example
K M Description Drug name Drug target Optimal logic model Page in SD1
1 1 Single predictor 21 (15%) PLX4720 RAF BRAF 41
1 2 2-input AND 11 (8%) Paclitaxel Microtubules CDKN2A & TP53 64
1 3 3-input AND 9 (6%) Cytarabine DNA synthesis CDKN2A & ¬ EGFR & ¬ SMAD4 14
1 4 4-input AND 31 (22%) KIN001-102 Akt1 ¬ APC & ¬ BRAF & ¬ EGFR & ¬ KRAS 135
2 1 2-input OR 12 (8%) BEZ235 PI3K, MTORC PIK3CA | PTEN 55
3 1 3-input OR 17 (12%) AZD6244 MEK 1/2 BRAF | KRAS | NRAS 60
4 1 4-input OR 23 (16%) Afatinib EGFR, ERBB2 EGFR | ERBB2 | JAK2 | SMAD4 39
2 2 2-by-2 18 (13%) JQ12 HDAC (CDKN2A & ¬ SMAD4) | (¬ KRAS & ¬ TP53) 90
Table 1.  Overview of the optimal logic model complexity as determined by cross-validation across the set 
of 142 drugs. For each of the 8 model complexities (columns 1–3), this table states the number of drugs best 
explained by the indicated model complexity (column 4), as well an example of one drug, including drug name 
(column 5), drug target (column 6), the optimal logic formula (column 7) and the page in Supplementary Data 
1 with the standard LOBICO visualization of the inferred logic models for the indicated drug (column 8).
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(Supplementary Figure 5). Yet, many other strong models on GDSC, i.e. those with high statistical significance, 
did not lead to a significant prediction of drug response in CTRP (Supplementary Figure 6). Still, 5 of the 25 mod-
els (20%) that were statistically significant in the training phase also showed statistical significance in the CTRP 
validation cohort. Similar to Scenario 1, we found that in many cases multi-predictor models outperformed single 
predictor models also on the validation cohorts. Overall, strong logic models validate in CTRP, whereas this is 
not necessarily the case for weaker, yet still statistically significant models, and generalization of these models to 
different cell line panels should be approached with caution. See Supplementary Note 1 for details.
Use of continuous output yields more robust and accurate models. After LOBICO was success-
fully employed to infer sensible models of drug response, we set out to quantify the contribution of the use of the 
sample-specific weights. In other words, is it advantageous to use the distances from the continuous IC50s to the 
binarization threshold as sample-specific misclassification penalties? Or, would simply using binarized data as is 
done in standard logical data analysis15 as well as in a recent application to cancer cell line drug screening data13 
be equally informative?
To this end, we analyzed logic models under slightly different binarization thresholds. Specifically, we shifted 
the default threshold (t = 0.05) slightly downwards (t = 0.03) and upwards (t = 0.07) leading to, on average, 24% 
less and 22% more sensitive cell lines, respectively. As such, these parameter changes lead to a small (not insignif-
icant, yet also not substantial) change in the assignment of cases (sensitive cell lines) and controls (resistant cell 
lines). See Methods Section for details. Then, we ran LOBICO across these binarization thresholds with and with-
out the sample-specific weights. The logic models for a drug were inferred using the model complexity (defined by 
K and M) selected by CV for that drug in the standard setting, i.e. with the sample-specific weights and t = 0.05. 
We conjectured that small changes in the binarization thresholds should only moderately affect the inferred logic 
models, i.e. the models should be robust against these small changes.
In order to evaluate the robustness of the logic models we examined the feature importance (FI) scores of these 
models across the binarization thresholds. Specifically, we used the correlation of FI scores across the binarization 
thresholds as a measure of robustness, where the degree of change in the FI scores is inversely proportional to the 
robustness of the model. The FI score for a feature is defined as the increase in error when the feature is left out 
of the inferred logic model (Equation 9). The FI scores are not only based on the optimal logic model, but also 
on other good (suboptimal) logic models that are identified by the ILP solver. (See Methods Section for details.) 
Across the 72 statistically significant models we found that most features are essential, i.e. have a high FI score, for 
a specific drug. However, BRAF, CDKN2A and TP53 play an important role in explaining the drug response for 
many of the drugs in our panel (Supplementary Figure 7). As an example of FI scores, Fig. 3a depicts the FI scores 
of the 60 gene mutation features for the PI3K/mTOR inhibitor BEZ235. From this panel it is clear that two fea-
tures, PTEN and PI3KCA, are important in explaining BEZ235 response. More importantly, when sample-specific 
weights are employed, the FI remains robust across different values of the discretization threshold.
Also across the remaining drugs the use of the continuous output via sample-specific weights resulted in a 
substantially smaller variation in the FI scores across the binarization thresholds (Fig. 3b). Particularly, the FI 
scores for the logic models across the three thresholds had an average Pearson correlation coefficient larger than 
0.75 for all but two drugs (99% of the drugs), and 106 drugs (75% of the drugs) had a correlation larger than 0.95. 
This was in stark contrast to the logic models based without the sample-specific weights, where 93 drugs (65%) 
had a correlation larger than 0.75 and only 44 (31%) had a correlation larger than 0.95. From this observation 
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(y-axis). Each point represents one of the 142 drugs. Statistically significant models are highlighted in blue. Multi-
predictor models that have a CV error lower than 0.35 and at least a 25% improvement upon the single predictor 
model are highlighted in magenta. The two examples discussed in the text are highlighted in bold typeface.
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we conclude that the use of the sample-specific weights based on the continuous output makes the inferred logic 
models less sensitive to small changes in the dataset, i.e. more robust.
We also assessed the robustness of the logic models across the CV training folds. Here, we observed a sim-
ilar pattern, although the difference between using and not using sample-specific weights was less pronounced 
(Supplementary Note 2 and Supplementary Figure 8). Logic models inferred from the randomly sampled subsets 
of cell lines, i.e. the CV folds, showed more variability in feature importance scores than the models inferred 
with slight changes in the binarization threshold. This is not surprising, since the in- or exclusion of samples, 
especially those far away from the binarization threshold, can have a large effect on the optimization function 
(Equation 1) and thus the inferred optimal logic model. One such example in our dataset is represented by the 
drug Bicalutamide, which has the poorest CV performance (point in the top right in Fig. 2). Here, the cell line 
HT-3 has an extremely low IC50, much lower than all other sensitive cell lines (see Supplementary Data 1). This 
results in a disproportionally large weight for this sample (its weight is 0.21), whereas the total weight of all 657 
cell lines, for which IC50s have been obtained, is 1. This analysis hints at an important weakness of our approach: 
Outliers, i.e. samples with erroneously large or small output values, have a large effect on the inferred logic model. 
In general, it is thus very important that outliers are detected and removed before performing a LOBICO analysis.
Studying the robustness across different CV folds led us to investigate the number of cell lines needed to 
effectively run LOBICO. We implemented a subsampling strategy that showed a substantial influence on perfor-
mance and robustness. Specifically, whereas for 51% of the drugs LOBICO inferred logic models that are robust 
and predictive when using all cell lines, this number decreased to 25% of the drugs when using 50% of the cell 
lines (around 300 cell lines). With a subsampling frequency of 10% (around 60 cell lines) only 18% of the drugs 
had a robust and predictive model (Supplementary Note 3 and Supplementary Figure 9). The balance between 
the sensitive and the resistant class as well as the classification performance are important factors in determining 
whether LOBICO can be effectively run for a smaller cell line panel.
Next, we employed a ‘ground truth’ mapping between drugs and mutations to gauge whether the use of con-
tinuous output variables led to more accurate models. This mapping, which is based on the annotation of the drug 
targets and expert knowledge, links 49 drugs to one or more of the 60 gene mutation features (Supplementary 
Data 2). For each of these 49 drugs, we analyzed the FI scores of the ground truth features. In this case, we used 
‘aggregated’ FI scores, which were not just based on the optimal and suboptimal models from the model complex-
ity with the lowest CV error, but also on the other model complexities that have a CV error equal or smaller than 
the CV error for the single predictor model (K = 1, M = 1). These aggregated FI scores provide a more compre-
hensive landscape of the importance of gene mutations in explaining drug response (Fig. 3a).
For 19 of the 49 drugs, the total aggregated FI scores of the ground truth features were not larger than 0.05, 
both for the logic models with as well as without the sample-specific weights (Fig. 3c). In these cases, the ground 
truth features did not explain the observed variation in drug response. For 26 of the remaining 30 drugs, the logic 
models with sample specific weights had larger FI scores for the ground truth features versus only 4 for the logic 
models without sample specific weights. Moreover, for 7 drugs, the use of the sample specific weights increased 
Row Scenario 1 2
Training dataset GDSC344 GDSC370
Validation dataset CTRP344 CTRP344
# % # %
1
Training
drugs (models) 37 46
2 MP models 24 65 34 74
3 predictive models 18 49 25 54
4 predictive MP models 11 61 21 84
5
Validation
drugs (models) 37 100 39 85
6 MP models 19 51 12 31
7 validated predictive models 5 28 5 20
8 validated predictive MP models 4 80 3 60
Table 2.  Overview of the CTRP validation analyses. LOBICO models were trained on 344 cell lines in 
our data (GDSC344) and validated on the same cell lines in CTRP (CTRP344) (Scenario 1, same cell lines 
for training and validation), and trained on 370 cell lines unique to our dataset (GDSC370) and validated on 
CTRP344 (Scenario 2, different cell lines for training and validation). Rows 1 to 4 list results on the training 
datasets. Specifically, Row 1 lists the number of drugs (or models) that were run on the GDSC dataset. Row 2 
lists, of the models in Row 1, the number and percentage for which a multi-predictor model was better than a 
single predictor model. Row 3 lists, of all models in Row 1, the number and percentage of ‘predictive models’, 
i.e. the models that showed significant differences in drug response values (IC50s) for the cell lines predicted to 
be sensitive and resistant. Row 4 lists, of the predictive models, the number and percentage comprising multi-
predictor models. Rows 5 to 8 list results on the validation dataset. Specifically, Row 5 lists, of the models run on 
the training data, the number and percentage that could be run on CTRP. Row 6 lists of the models listed in Row 
5, the number and percentage for which a multi-predictor model was better than a single predictor model. Row 
7 lists, of the predictive models on the GDSC training data, the number and percentage of ‘validated’ models, 
i.e. the models that showed significant differences of drug response values (AUCs for CTRP) for the cell lines 
predicted to be sensitive and resistant. Finally, Row 8 lists, of the validated models, the number and percentage 
of multi-predictor models. MP: multi-predictor.
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the importance of the ground truth features by at least 0.1. These 7 drugs included the PI3K/mTOR inhibitor 
BEZ235, 2 BRAF inhibitors and 4 small molecule inhibitors that target PDGFRA and KIT mutants, two of which 
also target FLT3 mutants, according to the ground truth mapping. Amongst the sensitive cell lines for these 
drugs, those with the smallest IC50s, i.e. the most sensitive ones, indeed harbored mutations in the ground truth 
features. This explains the increased accuracy of the logic models with sample-specific weights of retrieving the 
ground truth features.
The use of sample-specific weights is a prominent feature of LOBICO that sets it apart from traditional meth-
ods that use binarized data. The results presented in this section demonstrate that the use of the continuous out-
put leads to more robust and accurate logic models.
LOBICO finds logic models around a user-defined operating point. A binary classifier can make 
two kinds of mistakes: false positives (Type I errors) and false negatives (Type II errors). The trade-off between 
the false positive rate (FPR, 1-specificity) and false negative rate (FNR, 1-sensitivity) defines the operating point 
of the classifier. The practical application of a binary classifier in any domain is determined by its operating point, 
the prevalence of positives in the population of interest and the costs, financial or otherwise, that are associated 
with false positives, false negatives and the test itself.
For example, many medical screening tests, which are relatively inexpensive and generally non-invasive, have 
high sensitivity and are useful for ‘ruling out’ patients that test negative. For example, a mammogram to screen 
for breast cancer has a sensitivity of 80% and a specificity of 90%17. (It should be noted that periodic screening 
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Figure 3. LOBICO’s use of continuous output leads to robust and accurate models. (a) Heatmaps depicting 
the feature importance (FI) scores across the 60 gene mutations for the logic models inferred to explain the 
drug response to the PI3K/mTOR inhibitor BEZ235. The upper heatmap represents FI scores for the 2-input 
OR model (K = 2, M = 1) using three different binarization thresholds for logic models with binarized output, 
i.e. not using the sample-specific weights. The middle of the three heatmaps represents the same FI scores, 
but for logic models with continuous output, i.e. using the sample-specific weights. The bottom two heatmaps 
depict FI scores aggregated across all model complexities, using the standard binarization threshold (t = 0.05), 
for both the logic models with and without the sample-specific weights. The labels of the gene mutations 
with a large FI in any of these heatmaps are printed below. The ‘ground truth’ features, i.e. the expected or 
annotated targets of this drug, PTEN and PIK3CA, are printed in bold. (b) Scatter plot with the average Pearson 
correlation coefficients of the similarity of FI scores across the binarization thresholds for inferred logic models 
without (x-axis) and with (y-axis) the sample-specific weights. Each point represents one of the 142 drugs. The 
correlation scores are computed using the model-complexity-specific FI scores. The grey bars on top and to the 
right of the scatter plot represent histograms of these correlation scores for models without and with the sample-
specific weights, respectively. (c) Scatter plot with the importance of the ground truth features for inferred logic 
models without (x-axis) and with (y-axis) the sample-specific weights. Each point represents one of the 49 
drugs, for which ground truth features were available. The importance scores of the ground truth features were 
derived from aggregated FI scores.
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amounts to a large total number of false positives as evidenced by the fact that half of the women screened in the 
US will receive a false positive mammogram in any 10-year period18).
The implementation of LOBICO as an integer programming problem allows one to add constraints to ensure 
that solutions meet predefined statistical performance criteria, such as a minimum specificity. We have applied 
lower bounds on the sensitivity and specificity by adding additional constraints to the ILP (see Equations 10 
and 11). If a solution is found, the corresponding logic model is guaranteed to meet these constraints. By setting 
various lower bounds on the sensitivity and specificity we can probe the receiver-operator-characteristic (ROC) 
space. In that way we can uncover logic models possibly employing different features at different operating points. 
Note that this analysis is quite different from the classical ROC analysis, where the same model is evaluated with 
different thresholds on the output parameter.
For the 25 drugs with the lowest CV error in the original analysis, we ran LOBICO with an array of sensitivity 
and specificity constraints covering the complete ROC space in intervals of 0.05. The optimal solution for each 
combination of sensitivity and specificity was again determined by CV. Note that the inclusion of the constraints 
could lead to different model complexities having the smallest CV error. The Pareto front of solutions is formed by 
the logic models that perform best in terms of the tradeoff between sensitivity and specificity. This front is equiv-
alent to the ROC curve, although the model at each operating point is different. We observed a large variation in 
the logic models across this curve, both in terms of the genes that were present in the models as well as the model 
complexity (Supplementary Data 3).
Figure 4a depicts the logic models in the ROC space for a single drug: MEK inhibitor AZD6244 (brand 
name Selumetinib), which is currently in clinical trials. Mutations in the gene BRAF clearly play an important 
role in explaining the drug response in the cell line panel, since BRAF is found in almost all solutions in the 
ROC space. The most specific solution near the bottom-left of the curve (FPR < 5%) states that BRAF mutants 
that neither have a CDKN2A nor a TP53 mutation are sensitive to this drug. This high specificity solution can 
be termed a ‘rule in’ solution, because due to the low FPR, cell lines (or, potentially in the future, patients) that 
carry a BRAF mutation and are CDKN2A or TP53 wild-type are very likely to respond to this drug. However, 
this solution explains only slightly more than 20% of the sensitive cell lines (true positive rate (TPR) ≈ 20%). 
Around the middle of the ROC curve, we observed a 3-input OR solution consisting of BRAF, KRAS and 
NRAS, the latter two being part of the RAS protein family, which is directly upstream of BRAF, MEK and ERK 
in the MAPK pathway. This solution has a TPR slightly below 60% and a FPR < 30%. At the top-right of the 
ROC curve, LOBICO provided a high sensitivity solution (TPR > 95%) that did not contain BRAF. This 4-input 
AND model predicts that cell lines that are wild-type (WT) for PIK3CA, RB1, STK11 mutations and that do 
not contain the EWS-FLI1 gene fusion, will respond to the drug. Another way to interpret this solution is that 
cell lines that have a mutation in either PIK3CA, RB1, STK11 or that contain the EWS-FLI1 gene fusion are 
resistant to the drug with a very high degree of certainty (FPR < 5% for identifying resistant cell lines). This 
high sensitivity solution can be termed a ‘rule out’ solution, as cell lines (or potentially patients) that satisfy this 
rule will most likely not respond to this drug.
Across the 25 drugs, there were 6 inhibitors of MEK or RAF, 2 inhibitors of Phosphoinositide 3-kinase 
(PI3K) and 2 inhibitors of Aurora kinase (AURK). The logic models across the ROC space displayed high sim-
ilarity within these three groups (Supplementary Figure 10). Figure 4b–d show the average FI scores of the 
high-specificity (‘rule in’) solutions and the high-sensitivity (‘rule out’) solutions. As already observed with the 
MEK-inhibitor AZD6244, mutations in BRAF and NRAS are indicative of drug response with high specificity 
for the MEK/RAF inhibitors. Conversely, the high importance scores for wild-type RB1 and PIK3CA in the high 
sensitivity solutions indicate that RB1 and PIK3CA mutants are resistant to these inhibitors. These observations 
fit within the current ideas on oncogenic signaling, as mutations in the tumor suppressor RB1 and oncogene 
PIK3CA can lead to uncontrolled cell growth by activating pathways other than the MAPK pathway that these 
inhibitors are targeting19,20. For the PI3K and AURK inhibitors we observed that cell lines with a mutation in the 
transmembrane receptor NOTCH1 are responsive with high specificity. KRAS and, noteworthy, PIK3CA mutants 
remain resistant to these drugs.
The ability to uncover logic models around predefined operating points is an important requirement for prac-
tical application of such models. The implementation of additional constraints in the ILP formulation of LOBICO 
enabled us to systematically probe the ROC space and uncover logic models for different operating points of 
interest. To the best of our knowledge, LOBICO is the first method to provide this important capability.
Discussion
Generally speaking, classification and regression approaches are primarily focused on prediction performance. 
Today’s state-of-the-art methods use complicated computational frameworks and data transformations to opti-
mize how well the model fits the data. These models have little bearing on the mental model of the person using 
the approach. The interpretation of the model, if possible at all, is typically limited to a ranked list of important 
features.
Here, we have presented LOBICO, which, although also optimizing data fit, was developed specifically to pro-
duce models that are intuitively understandable. It is important to recognize that performance and interpretation 
form a trade-off; by constraining a model to be simplistic enough to enable interpretation, one loses the freedom 
that a complex model can be used to achieve a better representation of the data. LOBICO generates small and 
robust logic models of binary input features that explain a continuous output.
These models, which fit with standard formal reasoning, allow a researcher to easily assimilate the model with 
his or her domain. We suggest that the use of interpretable models is crucial in any scientific discipline, where 
researchers, not machines, generate hypotheses, gain novel insights and decide on further experimentation.
We have demonstrated the application of LOBICO on a large cancer cell line panel by linking logic combina-
tions of gene mutations to drug response. These logic models are easily integrated into current thinking based 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:36812 | DOI: 10.1038/srep36812
around stratifying patient populations using individual and combinations of gene mutations. LOBICO is, how-
ever, a general framework that can be applied to all research questions that can be described as a mapping from 
binary input features to a continuous output variable. For example, we successfully applied LOBICO to a cross of 
two natural yeast strains, the offspring of which were phenotyped for sporulation efficiency (Supplementary Note 
4 and Supplementary Figure 11). Importantly, although most (biological) measurements are not binary, they are 
often amenable to binarization or, at least, a binary interpretation. The use of binary variables allows for standard 
formal reasoning. That is, if the relation between variables is described using logic, it can be easily understood and 
reasoned with. An argument against such binarization is the loss of information. In the models that we propose 
the continuous information of the phenotype variable is retained in the form of sample-specific weights, which, as 
we have shown, leads to more robust models. This is achieved by splitting the continuous phenotype into a binary 
vector and a vector with sample-specific weights. We envision that LOBICO has many applications, both within 
biology as well as in other domains. An important consideration for applying LOBICO, however, is that the data-
set at hand has the statistical power that enables one to detect logical relationships that explain the phenotype of 
interest. For example, most genome-wide association studies of complex traits lack compelling statistical support 
for epistatic interactions, or the relative magnitude of statistical epistasis is small21.
There are certain considerations about the applicability of LOBICO. First, LOBICO solves an NP-hard prob-
lem (Supplementary Note 5). We observed that the ILP solver can quickly traverse the search space of logic com-
binations when searching for small logic models. When looking for large models, on the other hand, the search 
space quickly explodes and it becomes prohibitive to find an optimal solution. However, we generally restrict 
LOBICO from inferring large models as they tend to overfit and are less interpretable.
We note that logic regression (LR) implements another search strategy based on simulated annealing, which 
also achieved a good performance on our dataset (Supplementary Note 6). In comparison, LR cannot guarantee 
that the obtained solution is optimal nor can it incorporate statistical performance constraints, which is the most 
relevant scenario for practical applications.
Second, the number of features and correlation structure within the feature space have a large impact on the 
feasibility of finding an optimal solution within a reasonable time. Large numbers of features drastically increase 
the search space. Hence, feature selection may be a prudent preprocessing step. When preselecting features, it 
would no longer be guaranteed that the optimal logic model is found. However, experiments on the cancer cell 
line panel show that features employed by the optimal logic model have high importance scores both in linear 
and non-linear regression models (Supplementary Note 7 and Supplementary Figure 12). Thus, these methods 
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Figure 4. LOBICO finds solutions at different operating points. (a) ROC space with LOBICO solutions to 
explain drug sensitivity to the MEK1/2 inhibitor AZD6244. Blue crosses indicate the TPR and FPR at which the 
solution was found. The logic formula of the solutions is printed next to the blue crosses. The color of the genes 
in a formula indicate their FI. Colors range from black (moderately important) to bright red (highly important). 
For comparison, the best single predictor solutions are visualized in green. Pink arrows point to solutions 
discussed in the text. The inlay depicts the histogram of IC50s for AZD6244 together with the binarization 
threshold, which divides the cell lines into 91 cell lines that are sensitive to AZD6244 and 515 that are resistant. 
(b) Average FI scores for a group of 6 MEK/RAF inhibitors (including AZD6244), for high specificity solutions 
(orange) and high sensitivity solutions (magenta). High specificity solutions were defined as solutions with 
FPR < 10%. Conversely, high sensitivity solutions were defined as solutions with TPR > 90%. The FI scores of all 
solutions on the Pareto front (ROC curve) that met these respective criteria across the six drugs were averaged. 
We distinguished between positive terms, indicating mutations (Mut.) and negated terms, indicating wild-type 
(WT). The two genes with the highest average FI score as mutants were printed at the top of their FI bar. The 
two genes with the highest average FI score as wild-types were printed at the bottom of their FI bar. (c,d) Similar 
to (b), but for a group of two PI3K inhibitors and a group of two AURKA/B inhibitors, respectively.
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might be useful for feature selection when LOBICO is to be applied to datasets with a prohibitively large number 
of features. Alternatively, expert knowledge can be used to preselect a smaller set of features. An advantage of the 
latter approach is that these features make sense to the domain experts and will lead to more easily interpretable 
models.
Correlated features are problematic, not only for LOBICO, but for most (sparse) linear or non-linear classifi-
cation and regression models. Highly correlated features are effectively interchangeable. In practice, this means 
that only one feature is selected or that the importance in the model is spread across these features. An additional 
disadvantage for LOBICO is that the ILP solver will spend a long time deciding which of the correlated features 
should be part of the optimal solution. Also, from the perspective of interpretation, correlated features can lead to 
ambiguity and should preferably be dealt with prior to performing a LOBICO analysis.
The implementation of LOBICO as an ILP framework offers substantial advantages and possibilities. Using 
sophisticated ILP solvers, LOBICO traverses the huge search space of logic combinations fast enough for appli-
cation to large datasets involving multiple model complexities and cross-validation. An argument against logical 
analysis is the loss of information when binarizing continuous data. The ILP formulation allows LOBICO to 
retain the continuous information in the form of sample-specific weights, which, as an added benefit, leads to 
robust models. Further, constraints guaranteeing predefined statistical performance criteria can be easily incor-
porated into the ILP framework, giving the logic models direct practical applicability.
A straightforward extension includes adjusting the ILP formulation to prioritize or even require certain fea-
tures to be part of the inferred logic model. Also, certain combinations of features can easily be allowed or dis-
allowed in the model. Furthermore, biological networks can be captured by ILP constraints, possibly reducing 
the search space and leading to logic models that reflect network biology. Another avenue for feature engineer-
ing for logic models based on cancer mutations would be the inclusion of mutually exclusive or co-occurring 
mutations22,23 as single features. These ideas will be explored in future research.
Methods and Materials
Cancer cell line dataset. We used a slightly expanded version of a previously published cancer cell line 
dataset14. Specifically, our dataset contained 714 cell lines and 142 drugs instead of 639 and 130, respectively, in 
the original publication. Although capillary sequencing was performed for 64 genes, our dataset only included 
the 54 genes for which at least one mutation or copy number aberration was found. A gene was called mutated 
when it had a point mutation, a small insertion or deletion as determined by capillary sequencing, or when it 
was highly amplified or homozygously deleted based on copy number arrays. This strategy of lumping together 
these genomic aberrations to derive mutated genes is identical to the original work14. Additionally, we included 
6 known oncogenic gene fusions, resulting in 60 mutation features. The drug screening dataset is incomplete, i.e. 
not all 142 drugs have been screened across all 714 cell lines. In total 81,700 IC50s were measured and 19,688 
(19%) were missing values. For the large majority of drugs, IC50s were obtained for between 600 to 700 cell lines. 
Since we applied LOBICO to each drug separately, cell lines that lack an IC50 were not used. We did not impute 
missing IC50s. In this work, IC50s were recorded as the natural logarithm of the half-maximal inhibitory μ M 
concentration. Complete data and information on cell lines, the binary mutation matrix, drugs and IC50s are 
found in Supplementary Data 2 and 4. Additional information on these data is found in14,24 and on the Genomics 
of Drugs Sensitivity in Cancer webpages (http://www.cancerrxgene.org/).
Binarization thresholds of the IC50s. The binarization threshold for each of the drugs was automatically 
determined using a heuristic outlier procedure, which consists of four steps:
1. Upsampling. For a drug, we gathered the IC50s and their confidence intervals of all (n) cell lines that were 
screened for that drug. Then, for each cell line, we took the IC50 and the confidence interval and used this 
to define a normal distribution. Specifically, the mean of this normal distribution was the IC50 and the 
standard deviation was the average difference between the IC50 and the lower and upper bound of the 
confidence interval. We sampled 1,000 data points from this normal distribution and repeated that for all 
cell lines, leading to 1,000 · n data points in total.
2. Density estimation. We performed kernel density estimation on the 1,000 · n data points using as kernel a 
normal distribution with bandwidth (standard deviation) 0.5. This kernel density estimate, f, is defined on 
the interval from the minimum value of the 1,000 · n data points, f min, to the maximum value, fmax, and was 
normalized such that ∫ =f x dx( ) 1f
f
min
max
.
3. Modeling the population of resistant cell lines. The population of resistant cell lines was modeled as a normal 
distribution. We used the mode (highest point) in f as the mean, μ, of this distribution. This choice was 
based on the expectation and previous observation that the large majority of cell lines is resistant to a 
drug14. To compute the standard deviation of this distribution, σ, we first computed the parameter θ, which 
marks the divide between sensitive and resistant cell lines. θ was computed using the following rules. 
i. θ is the maximum value, where the derivative f′ is zero, i.e. f′ (θ) = 0, under the constraints that θ < μ, 
f(θ) < 0.8 · f(μ) and ∫ > .
θ f x dx( ) 0 05
f min
.
ii. If no such value exists, θ is the maximum value, where the second derivative f ′ ′ is zero, i.e. f ′ ′ (θ) = 0, as 
well as f ′ ′ ′ (θ) > 0, again under the constraints that θ < μ, f(θ) < 0.8 · f(μ) and ∫ > .
θ f x dx( ) 0 05
f min
.
iii. If no such value exists, θ was set to f  
min.
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If θ is found under rule i., this indicates bimodality in f, i.e. there is another peak in the distribution to the left of 
μ, which represents the distribution of sensitive cell lines. Similarly, if θ is found under rule ii., there is a marked 
change in the slope of f, which points to the distribution of sensitive cell lines. The standard deviation, σ, is com-
puted as the median distance of all data points within the interval [θ μ]from μ. Finally, the population of resistant 
cell lines is represented by the Normal distribution N(μ, σ2), which we denote by g.
4. Evaluating the cumulative normal distribution to find the binarization threshold. The binarization threshold, 
b, is controlled by parameter t. Specifically, b is chosen such that the cumulative normal distribution 
function at b equals t, i.e. ∫ =−∞ g x dx t( )
b . The default setting for t is 0.05. Cell lines with IC50s smaller 
than b are called sensitive, whereas cell lines with IC50s larger than or equal to b are called resistant.
Supplementary Figures 13, 14 and 15 provide a visual description of the four-step-procedure to binarize IC50s 
for three different drugs, where rule i., ii., and iii. were used to find θ, respectively. Binarization thresholds (for 
t = 0.05) are found in Supplementary Data 2.
LOBICO. The goal of LOBICO (Logic Optimization for Binary Input to Continuous Output) is to construct a 
Boolean logic function that optimally maps the binary variables of an input dataset to a continuous output varia-
ble. LOBICO is an extension to the work of Kamath et al.25, which describes a way to solve the Boolean Function 
Synthesis Problem (BFSP) using integer linear programming (ILP). See Supplementary Note 5 for a description 
of the BFSP. Similarly to the BFSP, LOBICO is an NP-hard problem (also in Supplementary Note 5).
LOBICO has three main inputs:
1. X, a N × P binary matrix with N samples characterized by P binary features x1, x2, … , xP. The P columns of 
X are denoted as x1, x2, … , xP.
2. y, a N × 1 binary vector, which is the binarized version of the continuous output variable.
3. w, a N × 1 continuous vector with weights for each of the N samples.
LOBICO finds an optimal logic function Θˆ that minimizes the weighted sum of incorrectly inferred samples:
′Θ = −
Θ
ˆ w y yarg min ( ) (1)
T
where, y′ = Θ (X) is a binary vector with the inferred binary labels. The logic functions inferred by LOBICO are in 
disjunctive normal form (DNF), a generalized logic notation also known as the sum-of-products expression. The 
complexity of a DNF is determined by two parameters: K, the number of disjunctive terms and M, the maximum 
number of selected features per disjunctive term.
ILP formulation of LOBICO. The ILP formulation to find an optimal Θˆ given X, y, w, K and M employs 
three variables: First, selection variables are introduced to determine which variable is part of a disjunctive term.
=




s
x k
x k
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Second, auxiliary variables t1, … , tK, which are vectors of length N, are used to represent the disjunctive terms. 
Third, the disjunctive terms are combined in the final disjunction resulting in the inferred binary output variable 
y′ . Figure 5 presents a graphical overview of the variables used in the ILP formulation.
The complete ILP formulation is given below.
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Following is a brief interpretation of the equations. The objective function in Equation 4 is the ILP formulation 
of Equation 1 and thus represents the weighted sum of incorrectly inferred samples, which should be minimized. 
The constraints in Equation 5 ensure that xp and its negation x p are not simultaneously part of the same disjunc-
tive term. The constraints in Equation 6 ensure that the total number of selected features in a disjunctive term 
does not exceed M. Equation 7 encodes the AND-gates that define the K disjunctive terms. The output of the 
AND-gate tnk is only 1 for those samples, where the binary data in X agrees with all selected features, i.e. 
= ∀ = = ∀ ′ =x p s x p s1 : 1, 0 : 1np pk np pk . In that case, the two summations in the middle part of the equation 
add up to P, thereby constraining tnk to 1. Equation 8 encodes the OR-gate, which combines the K disjunctive 
terms in the inferred binary output variable y′ .
Feature importance scores. Feature importance (FI) scores are based on the activity measure of variables 
in Boolean networks26,27. The importance score of feature a is defined as:
′= | ′ − | − | − |w y y w y yI ( ) ( ) (9)a a
T T
It represents the increase in the weighted sum of incorrectly inferred samples (Equation 1), henceforth called 
error, when comparing the optimal solution ′ = Θˆy X( ), resulting in the error wT(|y′ − y|), with Θˆa, the optimal 
solution where feature a is left out of the model, resulting in the error | −′w y y( )a
T .
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Figure 5. 3-layer Boolean circuit representing the structure of the LOBICO ILP formulation. In Layer 1 
variables s11, … , sPK are used to select the inputs (x1, x2, … , xP) that are combined using a conjunction (AND 
gate) to create the K disjunctive terms in Layer 2. These disjunctive terms (the outputs of the AND gates) are 
represented by variables t1, … , tK. In Layer 3 the disjunctive terms are combined using a disjunction (OR gate) 
resulting in the inferred binary output variable y′ . This figure is adapted from Figure 2.1 in Kamath et al.25.
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In practice, leaving feature a out of the DNF is achieved by either setting all values of a to 1 in the case that 
feature a is part of a disjunctive term with at least one other feature, or setting all values of a to 0 in the case that 
feature a is the only feature in the disjunctive term. Features that are not part of the model (DNF) receive an 
importance score of 0.
See “Application to the cancer cell line panel” below, where we explain how we aggregated feature importance 
scores across suboptimal solutions, model complexities and CV folds to quantify the importance of gene muta-
tions in explaining drug sensitivity.
Sensitivity and specificity constraints. The ILP formulation, which includes both the actual output (y) 
and inferred output (y′ ), enables the straightforward implementation of constraints, which guarantee that the 
ILP solution meets certain performance statistics (provided that a solution actually exists). Specifically, we imple-
mented constraints on minimum sensitivity (also called true positive rate or recall), TPRmin, and minimum spec-
ificity, (also called true negative rate or one minus the false positive rate), TNRmin, as follows:
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Note that in Equation 10 ∑ = ynN n1  is the number of positives and ∑ ′∀ = yn y n: 1n  is the number of true positives. In 
Equation 11 ∑ −= y(1 )nN n1  is the number of negatives and ∑ − ′∀ = y(1 )n y n: 0n  is the number of true negatives.Using the notion of sample-specific weights (as represented by w), we defined ‘continuous’ versions of con-
straints on the sensitivity and specificity as follows:
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Visualizations of LOBICO solutions in the ROC space using the constraints on the ‘continuous’ sensitivity and 
specificity are found in Supplementary Data 3.
Application to the cancer cell line panel. LOBICO inputs. LOBICO was applied to each drug in the 
cancer cell line panel separately. The three main inputs for each LOBICO analysis were:
1. X, the N × P binary mutation matrix with N cell lines and P = 60 binary gene mutations. N differs per drug 
as not all drugs have been screened across all cell lines. For the large majority of drugs, N is between 600 
and 700.
2. y, the N × 1 binary vector indicating whether a cell line is sensitive (1) or resistant (0) to the drug. This vec-
tor is obtained by binarizing the continuous IC50s using the binarization threshold, which is determined as 
explained above.
3. w, a N × 1 continuous vector with weights for each of the N cell lines. w is simply the absolute difference 
between the IC50s and the binarization threshold, normalized per class:
=
−
⋅ ∑ −∀ =
w z b
z b2 (14)
n
n
m y y m: m n
here, zn is the continuous IC50 of cell line n and b the binarization threshold for the drug. The normalization 
ensures that both classes (sensitive and resistant) have the same total weight, i.e. 0.5. Note that ∑ =∀ w 1n n . In 
“Use of continuous output yields more robust and accurate models”, where we compared to the setup in which we 
did not use the sample-specific weights, =
⋅∑∀ =
wn
1
2 1m ym yn:
.
Statistical performance constraints. For the analyses described in “LOBICO finds logic models around a 
user-defined operating point”, we systematically varied TPRmin (Equation 10) and TNRmin (Equation 11). For all 
other analyses in the paper, we did not employ the statistical performance constraints.
Model complexities. We applied LOBICO with eight different DNF complexities, i.e. we used all combinations of 
natural numbers K and M provided that K · M ≤ 4 (see Table 1).
Cross-validation. For each LOBICO analysis in the paper, a stratified 10-fold cross-validation (CV) strategy was 
employed.
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Permutation test. We implemented a straightforward statistical test to decide whether an inferred logic model 
performed significantly better than random. First, we took the inferred class labels (sensitive (1) and resistant (0)) 
of the inferred logic model when applied to the test folds in the CV. Here, the model complexity of the employed 
logic model was the optimal complexity according to CV. The binary vector was permuted 1,000,000 times and 
the error (i.e the sum of the weighted misclassified cell lines) associated with each permutation was computed 
and recorded. The permuted errors, the mean of which is 0.5, were compared to the original CV error. The per-
mutation test P-value was computed using EPEPT (Enhanced P-value Estimation for Permutation Tests)28,29. This 
was done for all 142 logic models. We derived q-values for each of the 142 P-values. A logic model was called 
statistically significant when both its p-value and q-value (FDR) were smaller than 0.01.
Feature importance scores. We computed two types of FI scores for the analysis of the drug response models:
1. Model-complexity-specific FI scores. The model-complexity-specific (MCS) importance of feature f is the 
non-zero average of the FI scores of feature f, If (Equation 9), obtained from the optimal solution and sub-
optimal logic models (if any) for particular model complexity (K and M). Often the suboptimal solutions 
differ only slightly in error with respect to the optimal model, but contain different features. (See “Solving 
the ILP using CPLEX” later in this section that explains how suboptimal solutions are found.) This means 
that the MCS FI score of feature f is the mean FI of f across all “good” logic models that contain feature f. 
Features that are neither part of the optimal logic model nor part of any suboptimal logic model get a score 
of zero. In this work, the sample-specific weights were normalized such that errors are between 0 and 1, 
with random prediction resulting in an expected error of 0.5 (Equation 14). Hence, FI scores are between 0 
and 0.5, although the large majority (about 90%) of the non-zero FI scores are smaller than 0.05, and only 
a small portion (about 5%) are larger than 0.1. The MCS FI scores were used in the robustness analysis 
(Fig. 3b and Supplementary Figure 8) and the ROC analysis (Fig. 4). They are displayed in Supplementary 
Data 1 and the upper part of Fig. 3a.
2. Aggregated FI scores. The aggregated importance of feature f is the non-zero average of the MCS FI scores 
of all model complexities that have a CV error equal or smaller than the CV error for the single predictor 
model (K = 1 and M = 1). Calculating the aggregated FI score involves averaging across the logic models 
based on all samples as well as the logic models based on the CV training folds. Hence, the aggregated FI 
scores provide a more comprehensive view of the importance of features in explaining the variation in 
the output variable. The aggregated FI scores were used in the ground truth analysis (Fig. 3c). They are 
displayed in Supplementary Data 2 and the lower part of Fig. 3a.
Solving the ILP using CPLEX. The ILP problems were solved using IBM ILOG CPLEX Optimization 
Studio V12.4, which is freely available for academic use. Importantly, ILP solvers guarantee optimal solutions 
(within a numerically small tolerance). Besides the optimal solution, we collected suboptimal solutions using 
CPLEX’s solution pool. Specifically, up to 25 solutions with a relative gap smaller than 0.1 were gathered using 
the default pool replacement strategy of replacing the least diverse solutions. We employed a time limit of 1 hour 
(3600 seconds) per ILP. Less than 1% of the ILP runs did not find the guaranteed optimal solution within this time 
limit (See Supplementary Figure 16). These solutions were all for 2 × 2 models. In these cases we used the best 
solutions found thus far. All other parameters were set to their default values.
LOBICO code availability. LOBICO is implemented in MATLAB and Python and is available through 
https://github.com/tknijnen/LOBICO.
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